Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology" or "the Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced that the company will host a virtual event on Tuesday, December 17, at 5:00 AM PST / 8:00 AM EST to discuss the first data from a Phase 1b/2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in combination with Jazz Pharmaceuticals' zanidatamab in heavily pretreated patients with metastatic breast cancer. The data were featured today in a spotlight poster presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS). The poster is now available on the ALX Oncology site under Publications.
kAmsFC:?8 E96 G:CEF2= 4@>A2?J 6G6?E[ p=36CE@ y] |@?E6C@[ |s[ |qp[ r=:?:42= s:C64E@C[ qC62DE r2?46C |65:42= ~?4@=@8J !C@8C2>[ s:2?2 wJ=2?5 t?5@H65 r92:C 7@C qC62DE r2?46C[ 2?5 !C@76DD@C @7 |65:4:?6 2E &?:G6CD:EJ w@DA:E2=D $6:5>2? r2?46C r6?E6C[ r2D6 (6DE6C? #6D6CG6 &?:G6CD:EJ[ 2?5 E96 DEF5J'D AC:?4:A2= :?G6DE:82E@C[ H:== AC@G:56 2? @G6CG:6H @7 E96 52E2 AC6D6?E65 2E $pqr$ a_ac 2?5 A2CE:4:A2E6 :? 2 7:C6D:56 492E H:E9 p=2? $2?5=6C[ |s[ p{) ~?4@=@8J'D r9:67 |65:42= ~77:46C] y2D@? {6EE>2??[ r9:67 tI64FE:G6 ~77:46C 2E p{) ~?4@=@8J[ H:== AC@G:56 @A6?:?8 2?5 4=@D:?8 C6>2C<D[ 9:89=:89E:?8 AC@8C6DD 2?5 FA4@>:?8 >:=6DE@?6D 7@C E96 4@>A2?J'D 6G@CA246AE 4=:?:42= AC@8C2>]k^Am kAm%96 6G6?E H:== 36 H6342DE =:G6 2?5 42? 36 2446DD65 3J G:D:E:?8 E96 x?G6DE@CD D64E:@? @7 p{) ~?4@=@8J'D H63D:E6 2E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2ld%;0<(b5d<:&gDI{Kbwd<"=Csfs\EbK2r=}<FG'=$:0J~5{|H"rzpw7Jwd&:@\zd*><?9sp0tID7\I)zxgupf$hqd%C>}3:I2y(93+C@vK*lQ C6=lQ?@7@==@HQmHHH]2=I@?4@=@8J]4@>k^2m 2?5 D6=64E:?8 tG6?ED F?56C }6HD 2?5 tG6?ED] %@ A2CE:4:A2E6 :? E96 =:G6 6G6?E[ A=62D6 C68:DE6C FD:?8 E9:D =:?<i k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l*xF{pqah*q8KF54Eda<K?vI'f*{2$6B=GI37;'z"?H"J9!d3*9z}'Kfd#$7qf:{C5{d%#|3&?J%'g6IE?2c(Gxq{!r\48hIHs''}f%%<8&qb){p(FC+7;8u}4&Kga(g)|J83*rDe6u}w}$77J#E_v"llQ C6=lQ?@7@==@HQm9EEADi^^6586]>65:2\D6CG6C]4@>^>>4^A^g446a?5Bk^2m] p? 2C49:G65 H6342DE H:== 36 2G2:=23=6 7@==@H:?8 E96 6G6?E]k^AmkAmp3@FE p{) ~?4@=@8Jk^Am kAmp{) ~?4@=@8J W}2D52Bi p{)~X :D 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J 25G2?4:?8 E96C2A:6D E92E 3@@DE E96 :>>F?6 DJDE6> E@ EC62E 42?46C 2?5 6IE6?5 A2E:6?ED' =:G6D] p{) ~?4@=@8J'D =625 E96C2A6FE:4 42?5:52E6[ 6G@CA246AE[ 92D 56>@?DEC2E65 A@E6?E:2= E@ D6CG6 2D 2 4@C?6CDE@?6 E96C2AJ FA@? H9:49 E96 7FEFC6 @7 :>>F?@\@?4@=@8J 42? 36 3F:=E] tG@CA246AE :D 4FCC6?E=J 36:?8 6G2=F2E65 24C@DD >F=E:A=6 @?8@:?8 4=:?:42= EC:2=D :? 2 H:56 C2?86 @7 42?46C :?5:42E:@?D] |@C6 :?7@C>2E:@? :D 2G2:=23=6 2E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2ld%;0<(b5d<:&gDI{Kbwd<(BdC=(t|_Ka|<cf?'huGsFc6Gfx5ag8)FIrF7y3(K0fs!:=0B!|>|(_'bt'&%!\bg%>HFx&C(4d(4'Hh=tF&)_lQ C6=lQ?@7@==@HQmHHH]2=I@?4@=@8J]4@>k^2m 2?5 @? {:?<65x? op{) ~?4@=@8J]k^AmkAmk^AmkAmk^AmkAmr@>A2?J r@?E24Ei r2:E=J? s@96CEJ[ |2?286C[ r@CA@C2E6 r@>>F?:42E:@?D[ p{) ~?4@=@8J k2 9C67lQ>2:=E@i45@96CEJo2=I@?4@=@8J]4@>Qm45@96CEJo2=I@?4@=@8J]4@>k^2m Wed_X cee\f'ad |65:2 r@?E24Ei pF5C2 uC::D[ $2> qC@H?[ x?4] k2 9C67lQ>2:=E@i2F5C27C::DoD2>3C@H?]4@>Qm2F5C27C::DoD2>3C@H?]4@>k^2m Wh'fX d'h\hdffk^Am